Delgocitinib maintains positive outcomes for chronic hand eczema in extension trial
Click Here to Manage Email Alerts
Key takeaways:
- Patients from the phase 3 DELTA 1 and 2 trials were enrolled in the DELTA 3 extension trial.
- Delgocitinib maintained positive outcomes and a consistent safety profile among patients with chronic hand eczema.
New data showed delgocitinib cream maintained symptom relief and treatment success in adults with chronic hand eczema, LEO Pharma announced in a press release.
Delgocitinib cream is an investigational topical pan-Janus kinase inhibitor that may treat moderate to severe chronic hand eczema. The new data from LEO Pharma were drawn from DELTA 3, a phase 3, single-arm, open-label, extension trial from DELTA 1 and DELTA 2.
“It is encouraging to see the level of consistency that these long-term results show, in line with the previous positive results from the pivotal DELTA 1 and 2 trials,” Kreesten Meldgaard Madsen, MD, PhD, chief development officer of LEO Pharma, said in the press release. “This condition can have a negative impact on patient quality of life, physical functioning and ability to work, and there are currently no topical treatments specifically approved for moderate to severe chronic hand eczema.”
Patients from DELTA 1 and 2 were treated with delgocitinib cream or vehicle twice daily for 16 weeks before enrolling in the 36-week DELTA 3 trial. Once enrolled, all patients previously receiving delgocitinib cream continued their treatment, whereas patients previously receiving vehicle switched to delgocitinib.
Results showed that DELTA 1 and 2 patients treated with delgocitinib cream maintained their prior improvement for the additional 36 weeks in DELTA 3.
Patients previously treated with vehicle also reached similar levels of success as delgocitinib-treated patients over the 36-week period. Additionally, delgocitinib’s safety profile in DELTA 3 was reportedly consistent with DELTA 1 and 2.
According to the release, LEO Pharma will conduct further analyses of the data to determine delgocitinib’s full potential in this indication. The company plans to submit detailed study results for scientific presentation and publication in the future.